When an application for a substantial amendment to an initial clinical trial is submitted, the competent Committee for the Protection of Individuals shall carry out the Part II assessment provided for in Article 7 of the aforementioned Regulation of 16 April 2014 within the time limits defined in Article 20 of that Regulation. The Committee shall issue a favourable, favourable subject to specific conditions or unfavourable opinion on this application.
If the Committee remains silent at the end of this period, the application is deemed to have been accepted.